Study of AHIST in Seasonal Allergic Rhinitis Patients
Status:
Withdrawn
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Objectives:
A) To gather pharmacodynamic measurements and assess blood levels of the active ingredients
in AHIST over the dosage interval period of 12 hours.
Hypothesis: Hysteresis curves plotting each active ingredient's blood levels over a 12-hour
dosage interval will substantiate S5 Symptom Diary scores (IE: evidentiary therapeutic window
data);
B) To report subjective scores by subjects rating the efficacy of a single dose AHIST in
relieving nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip over a
12-hour dosage interval.
Hypothesis: Greater than 66% of subjects will document clinically significant relief over a
12-hour period from one dose of AHIST;
C) Report any side effects or adverse drug reactions and rate the severity of any incidence.
Hypothesis: Not more than one patient will have an adverse event significant enough to
warrant withdrawal; side effects will be mild with the most frequently reported side effect
occurring in less than 10% of patients-drowsiness.